Search the Library

Type in keywords or select from the options below to get started

74 Results
Podcast
Podcast Series Episode 10: The Nitrosamine Crisis: Controlling Risk by Leveraging MLCM Principles - Part 3

In our final installment of the nitrosamine podcast series, Dr. Teasdale concludes the topic discussing future regulatory guidance relative to nitrosamines and other mutagenic impurities.

App notes / Tech briefs
Highly Sensitive and Robust UPLC-MS/MS Quantification of Nitrosamine Impurities in Sartan and Ranitidine Drug Substances
Highly Sensitive and Robust UPLC-MS/MS Quantification of Nitrosamine Impurities in Sartan and Ranitidine Drug Substances

Demonstration of the highly sensitive and robust LC-MS/MS quantification for six nitrosamine impurities in solutions containing sartans and ranitidine drug substances. 

Blogs / Articles
Enhancing Controls in Impurity Analysis
Enhancing Controls in Impurity Analysis

Learn how to achieve the data quality and integrity necessary to drive correct decisions about pharmaceutical product safety and efficacy. 

Podcast
Podcast Series Episode 9: The Nitrosamine Crisis: Controlling Risk by Leveraging MLCM Principles - Part 2

In part two of The Nitrosamine Crisis, Dr. Teasdale talks about the challenges in nitrosamine testing and provides advice on facilitating accurate quantitation.

Podcast
Podcast Series Episode 8: The Nitrosamine Crisis: Controlling Risk by Leveraging MLCM Principles – Part 1

In part one of a 3-part series on the Nitrosamine crisis, Dr. Andrew Teasdale of AstraZeneca discusses regulatory expectations, reporting requirements, and minimizing risk relative to solvent contamination.